US Stock Insider Trading | Revolution Medicines disclosed 1 insider transaction on February 10

K-LinePoet · 2026-02-11T21:59:33+00:00

Revolution Medicines discloses insider trading, Director GOLDSMITH MARK A purchased 24,000 shares on February 6, 2026, at $0.54 per share, totaling $13,000. The company focuses on developing targeted therapies for RAS-driven cancers and has strong drug discovery capabilities.

K-LinePoet

2026-02-11 21:59:33

Abstract generation in progress

On February 10, 2026, Revolution Medicines (RVMD) disclosed an insider transaction. Director GOLDSMITH MARK A purchased 24,000 shares on February 6, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
2026-02-10	Director	GOLDSMITH MARK A	2026-02-06	Buy	24,000	0.54	13,000
2026-01-23	Executive	Cislini Jeff	2026-01-21	Sell	908	115.60	105,000
2026-01-09	Executive	Horn Margaret A	2026-01-07	Sell	20,200	101.79	2,056,600
2026-01-09	Executive	Horn Margaret A	2026-01-07	Buy	23,600	29.80	703,100
2026-01-09	Executive	Anders Jack	2026-01-07	Sell	10,000	98.00	980,000
2026-01-09	Executive	Horn Margaret A	2026-01-07	Sell	1,700	102.90	174,900
2026-01-09	Executive	Horn Margaret A	2026-01-07	Buy	51,400	42.45	2,182,200
2026-01-09	Executive	Anders Jack	2026-01-07	Buy	10,000	42.45	424,500
2026-01-09	Executive	Horn Margaret A	2026-01-07	Sell	53,100	100.02	5,310,500
2025-12-18	Executive	Horn Margaret A	2025-12-16	Sell	4,847	76.82	372,300

[Company Information]

Revolution Medicines, Inc., founded in October 2014, is a Delaware-based company. It is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets involved in RAS-addicted cancers. The company possesses advanced structure-based drug discovery capabilities, grounded in deep knowledge of chemical biology and cancer pharmacology, along with innovative proprietary technologies capable of creating small molecules suitable for unconventional binding sites. Its understanding of the genetic drivers of cancer and adaptive resistance mechanisms, combined with strong drug discovery and medicinal chemistry capabilities, has guided the development of a deep pipeline targeting the RAS pathway and key signaling nodes within related pathways.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.